Across TCGA pan-cancer cohorts, HLA-DRB5 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of HLA-DRB5’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HLA-DRB5 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types HLA-DRB5 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

CCRCC, LSCC, and PDAC are the cancer types where HLA-DRB5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HLA-DRB5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.713	<.001	10	view →
LSCC	Male	III,IV	−1.212	<.001	8	view →
PDAC	Female	All	+0.909	<.001	6	view →
HNSC	Male	All	+0.398	.003	4	view →
LUAD	All	All	−0.316	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: HLA-DRB5 RNA expression & survival · all HLA-DRB5 data types